Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.53 |
| ▸ | PNMT | P11086 | 1/20 | 0.42 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.42 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.41 |
| ▸ | CFD | P00746 | 2/20 | 0.41 |
| ▸ | CDK8 | P49336 | 1/20 | 0.41 |
| ▸ | NOS3 | P29474 | 3/20 | 0.41 |
| ▸ | NOS1 | P29475 | 3/20 | 0.41 |
| ▸ | NOS2 | P35228 | 3/20 | 0.41 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.40 |
| ▸ | FYN | P06241 | 2/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.39 |
| ▸ | CETP | P11597 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1015839 | 0.98 | CSNK2A1 (0.55) | CSNK2A1PNMTENPP2TAAR1LOXL2 | |
| SCHEMBL2382129 | 0.86 | HTR7 (0.49) | CSNK2A1TAAR1LOXL2 | |
| SCHEMBL3791745 | 0.82 | LOXL2 (0.60) | CSNK2A1PNMTENPP2TAAR1LOXL2 | |
| SCHEMBL15349962 | 0.81 | FYN (0.54) | ENPP2CDK8SERPINE1FYNCNR1 | |
| SCHEMBL16160786 | 0.81 | BCL2 (0.47) | SERPINE1FYNCNR1CETP | |
| SCHEMBL2571833 | 0.80 | HRH3 (0.61) | CSNK2A1TAAR1LOXL2 | |
| SCHEMBL15525063 | 0.77 | MAOA (0.47) | CSNK2A1SERPINE1FYNCNR1PTGES2 | |
| SCHEMBL422337 | 0.76 | GRIN2D (0.51) | ENPP2SERPINE1CNR1 | |
| SCHEMBL3794460 | 0.76 | TAAR1 (0.70) | PNMTENPP2TAAR1LOXL2CFD | |
| SCHEMBL29400616 | 0.76 | TAAR1 (0.70) | CSNK2A1PNMTENPP2TAAR1LOXL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3452477-B1 | ADENINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | B C I PHARMA (BE) | 2023-09-13 | — | — | EP | disclosed |
| US-11236093-B2 | Adenine derivatives as protein kinase inhibitors | B.C.I. PHARMA (BE) | 2022-02-01 | — | — | US | disclosed |
| US-20190127379-A1 | ADENINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | B.C.I. PHARMA (BE) | 2019-05-02 | — | — | US | disclosed |
| US-8415479-B2 | Inhibitor of plasminogen activator inhibitor-1 | RENASCIENCE CO., LTD. (JP) | 2013-04-09 | — | — | US | disclosed |
| US-8293715-B2 | 10a-Azalide compound crosslinked at 10a- and 12-positions | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-10-23 | — | — | US | disclosed |
| US-20110237784-A1 | 10A-AZALIDE COMPOUND CROSSLINKED AT 10A- AND 12-POSITIONS | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-09-29 | — | — | US | disclosed |
| US-20110112140-A1 | INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 | RENASCIENCE CO., LTD. (JP) | 2011-05-12 | — | — | US | disclosed |
| EP-2272822-A1 | INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 | Renascience CO., LTD. (JP) | 2011-01-12 | — | — | EP | disclosed |
| EP-2177526-A1 | 10A-AZALIDE COMPOUND CROSSLINKED AT POSITION-10A AND POSITION-12 | Taisho Pharmaceutical Co. Ltd. (JP) | 2010-04-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237784-A1 | 10A-AZALIDE COMPOUND CROSSLINKED AT 10A- AND 12-POSITIONS | DCLRE1A, AZI2, CHD9 | CSNK2A1 3687/4885PNMT 4516/4885ENPP2 2110/4885 |
| US-11236093-B2 | Adenine derivatives as protein kinase inhibitors | ADK, TNNI3K, TNK2 | CSNK2A1 92/4885PNMT 1739/4885ENPP2 524/4885 |
| US-20190127379-A1 | ADENINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | ADK, TNNI3K, TNK2 | CSNK2A1 92/4885PNMT 1739/4885ENPP2 524/4885 |
| US-20110112140-A1 | INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 | SERPINE1, SERPINB1, SERPINC1 | CSNK2A1 3255/4885PNMT 3419/4885ENPP2 423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.